58 reports of this reaction
12.9% of all AVOBENZONE, HOMOSALATE, OCTISALATE, AND OCTOCRYLENE reports
#1 most reported adverse reaction
SKIN CANCER is the #1 most commonly reported adverse reaction for AVOBENZONE, HOMOSALATE, OCTISALATE, AND OCTOCRYLENE, manufactured by Kenvue Brands LLC. There are 58 FDA adverse event reports linking AVOBENZONE, HOMOSALATE, OCTISALATE, AND OCTOCRYLENE to SKIN CANCER. This represents approximately 12.9% of all 448 adverse event reports for this drug.
Patients taking AVOBENZONE, HOMOSALATE, OCTISALATE, AND OCTOCRYLENE who experience skin cancer should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SKIN CANCER is a frequently reported adverse event for AVOBENZONE, HOMOSALATE, OCTISALATE, AND OCTOCRYLENE, accounting for a significant proportion of all reports.
In addition to skin cancer, the following adverse reactions have been reported for AVOBENZONE, HOMOSALATE, OCTISALATE, AND OCTOCRYLENE:
The following drugs have also been linked to skin cancer in FDA adverse event reports:
SKIN CANCER has been reported as an adverse event in 58 FDA reports for AVOBENZONE, HOMOSALATE, OCTISALATE, AND OCTOCRYLENE. This does not prove causation, but indicates an association observed in post-market surveillance data.
SKIN CANCER accounts for approximately 12.9% of all adverse event reports for AVOBENZONE, HOMOSALATE, OCTISALATE, AND OCTOCRYLENE, making it one of the most commonly reported side effect.
If you experience skin cancer while taking AVOBENZONE, HOMOSALATE, OCTISALATE, AND OCTOCRYLENE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.